October 2021 OSE Immunotherapeutics Receives IDMC Approval to Continue “Atalante 1” Phase 3 NSCLC Clinical Trial of Tedopi®
October 2021 OSE Immunotherapeutics to Present at 4th Annual Immuno-Oncology: BD&L and Investment Forum